Placebo News and Research

RSS

Study generates promising data about sustained durability of Zyclara's efficacy versus cryosurgery alone

Results from a randomized study with Zyclara following cryotherapy in the treatment of actinic keratoses (AK) demonstrated Zyclara complemented the effectiveness of cryosurgery in reducing total AK count and achieving complete clearance of AK, according to data presented at the American Academy of Dermatology Summer Academy Meeting 2010 (Summer AAD), August 4 - 8.

7 Aug 2010

Clinical trials in Asia, Africa confirm safety, effectiveness of rotavirus vaccine

Two studies published online Thursday in the Lancet show that the rotavirus vaccine is safe and effective at preventing much of the gastrointestinal illness in developing countries, where rotavirus kills more than 400,000 children under age 5 annually, Reuters reports. Based on the findings in Asia and Africa, the studies' authors "urged the governments of developing nations to make the vaccines a priority," the news service writes.

7 Aug 2010

ViroPharma announces data on safety, efficacy of Cinryze to treat acute angioedema attacks

ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.

6 Aug 2010

V-101 shows safety profile in treating erythema of rosacea: Clinical study

Vicept Therapeutics, Inc., a privately held specialty biopharmaceutical company, announced positive results from a pharmacodynamic and pharmacokinetic clinical trial of the Company's lead product V-101, a topical cream under investigation for the treatment of erythema in patients with rosacea.

6 Aug 2010

Dyax announces first Phase 3 trial results of KALBITOR for acute HAE

Dyax Corp. announced today that results from EDEMA3, the Company's first Phase 3 trial evaluating KALBITOR (ecallantide) for the treatment of acute attacks of hereditary angioedema, were published in the August issue of The New England Journal of Medicine. KALBITOR, discovered and developed by Dyax, is available in the United States for the treatment of acute attacks of HAE in patients 16 years of age and older.

6 Aug 2010

Scientific findings reveal combination antibiotic therapy effective for ulcerative colitis

The link between Hormone Replacement Therapy and reduced risk of distal large bowel cancer in women; a promising combination antibiotic therapy for ulcerative colitis patients; and the high-rate of alcoholic liver disease mortality, are among the scientific findings featured in the August issue of The American Journal of Gastroenterology.

6 Aug 2010

Studies show biological agents play important role in maintaining remission in Crohn's disease

Biological agents may play an important role in maintaining remission in Crohn's disease, according to two new studies in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association Institute.

6 Aug 2010

Summer Academy Meeting highlights benefits of HPV, Herpes Zoster vaccines

Vaccines have a long history of successfully preventing disease and, in effect, improving the lives of countless Americans. Now, two serious diseases - human papillomavirus (HPV) and herpes zoster - could become a thing of the past as people better understand the safety and efficacy of vaccines to prevent these serious viral infections in specific populations.

6 Aug 2010

Repligen total revenue for first-quarter fiscal 2011 increases 39% to $7.01 million

Repligen Corporation today reported results for the first quarter of fiscal year 2011, ended June 30, 2010. Total revenue for the first quarter was $7,010,000 compared to total revenue of $5,061,000 for the first quarter of fiscal year 2010, an increase of $1,949,000 or 39%. Bioprocessing product revenue for the first quarter was $4,269,000 compared to $2,473,000 for the first quarter of fiscal 2010, an increase of $1,796,000 or 73%.

5 Aug 2010

BioCryst second-quarter total revenues increase to $7.6 million

BioCryst Pharmaceuticals, Inc. announced financial results for the second quarter and six months ended June 30, 2010.

5 Aug 2010

Vanda second-quarter 2010 revenues decrease by $4.1M

Vanda Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced financial and operational results for the second quarter and six months ended June 30, 2010.

5 Aug 2010

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the number of patients who achieved sustained virologic response, compared to control groups that received Peg/riba plus placebo.

5 Aug 2010

Genzyme, Isis announce results of two mipomersen phase 3 studies

Genzyme Corp. and Isis Pharmaceuticals Inc. today announced results of two phase 3 studies of mipomersen in patients who had high cholesterol levels while on maximally tolerated lipid-lowering therapy. In the study of patients with severe hypercholesterolemia, mipomersen reduced LDL-C, the primary endpoint, by 36 percent compared with a 13 percent increase for placebo.

5 Aug 2010

Alnylam second-quarter revenues increase to $26.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2010, and company highlights.

5 Aug 2010

Anthera second-quarter total operating expenses increase to $7.9 million

Anthera Pharmaceuticals, Inc., today announced financial results and business highlights for the second quarter ended June 30, 2010.

5 Aug 2010

Patients taking memantine show improvement in cognitive function, Merz analyses shows

In September 2009, the German Institute for Quality and Efficiency in Health Care concluded that no benefit has been proven for memantine in the treatment of Alzheimer's disease. An assessment now presented of 2 previously unpublished studies and new analyses by the manufacturer Merz do not change this conclusion. However, IQWiG describes the deficits of the newly provided analyses and specifically illustrates how the analyses would have to be presented in order to be considered in a benefit assessment.

4 Aug 2010

Contrave added to diet and exercise regimen can induce significant weight loss

Orexigen Therapeutics, Inc. announced the online publication of results from its COR-BMOD trial of Contrave (naltrexone SR/bupropion SR) in the journal Obesity. The COR-BMOD trial evaluated intensive behavior modification plus Contrave32 (32mg naltrexone sustained release (SR)/360mg bupropion SR) compared to BMOD plus placebo, in 793 overweight or obese patients.

4 Aug 2010

Arena reports lower net loss of $28.80M for second-quarter 2010

Arena Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2010, and recent developments, including the successful Pre-Approval Inspection, or PAI, of the company's Swiss drug product manufacturing facility by the US Food and Drug Administration, or FDA.

4 Aug 2010

Excaliard reports positive results from EXC 001 Phase 2 clinical trial for reducing scar severity

Excaliard Pharmaceuticals, Inc., today announced positive results from its Phase 2 clinical trial of EXC 001, a new chemical entity for reducing fibrosis. Results showed that EXC 001 treatment significantly reduced scar severity in subjects undergoing an elective abdominoplasty compared to placebo.

4 Aug 2010

MAP Pharmaceuticals reports net loss of $12.5M for second-quarter 2010

MAP Pharmaceuticals, Inc. today announced financial results for the second quarter ended June 30, 2010.

3 Aug 2010

Placebo News and Research

Study generates promising data about sustained durability of Zyclara's efficacy versus cryosurgery alone

Clinical trials in Asia, Africa confirm safety, effectiveness of rotavirus vaccine

ViroPharma announces data on safety, efficacy of Cinryze to treat acute angioedema attacks

V-101 shows safety profile in treating erythema of rosacea: Clinical study

Dyax announces first Phase 3 trial results of KALBITOR for acute HAE

Scientific findings reveal combination antibiotic therapy effective for ulcerative colitis

Studies show biological agents play important role in maintaining remission in Crohn's disease

Summer Academy Meeting highlights benefits of HPV, Herpes Zoster vaccines

Repligen total revenue for first-quarter fiscal 2011 increases 39% to $7.01 million

BioCryst second-quarter total revenues increase to $7.6 million

Vanda second-quarter 2010 revenues decrease by $4.1M

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Genzyme, Isis announce results of two mipomersen phase 3 studies

Alnylam second-quarter revenues increase to $26.6 million

Anthera second-quarter total operating expenses increase to $7.9 million

Patients taking memantine show improvement in cognitive function, Merz analyses shows

Contrave added to diet and exercise regimen can induce significant weight loss

Arena reports lower net loss of $28.80M for second-quarter 2010

Excaliard reports positive results from EXC 001 Phase 2 clinical trial for reducing scar severity

MAP Pharmaceuticals reports net loss of $12.5M for second-quarter 2010

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News